Literature DB >> 9801341

Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low-density lipoproteins.

S Koskinen1, C Enockson, M F Lopes-Virella, G Virella.   

Abstract

As part of our ongoing effort to develop a standardized competitive enzyme immunoassay for human autoantibodies to oxidized low-density lipoprotein (oxLDL), we have generated a reference human antibody standard and revised some of the conditions of the assay. The preparation of the standard involved purification of human anti-oxLDL antibodies by affinity chromatography using immobilized oxLDL. The total concentration of antibody in this purified human oxLDL antibody was established by adding the concentrations of immunoglobulin G (IgG), IgA, and IgM determined in the standard by radial immunodiffusion. The isolated antibody was used to calibrate a whole human serum standard, which was used to calibrate the assays to detect antibody in serum samples. We also revisited the general conditions for performance of our competitive assay. We determined that 1/20 was the ideal dilution for performing the absorption step, and that 1/20 and 1/40 were optimal dilutions to assay oxLDL antibody in unknown serum samples. We also established that the optimal concentration of oxLDL for absorption of free antibody in serum samples was 200 microgram of oxLDL/ml; no significant decrease in the reactivity of samples with immobilized oxLDL was observed when higher concentrations of oxLDL were used for absorption. The minimum detection level of the assay is 0.65 mg/liter. Because serum samples are diluted 1/20 and 1/40 for the assay, the minimal concentration of antibody detectable in serum is 20-fold higher, i.e., 13 mg/liter. The intraassay coefficient of variation calculated from seven determinations of three samples containing antibody concentrations of 240, 340, and 920 mg/liter ranged from 8 to 6.1%. The interassay coefficients of variation for sera with antibody levels of 100 to 594 mg/liter varied from 9.2 to 7.0%, and for isolated antibodies with concentrations of 52 to 111 mg/liter, the coefficients varied from 5.8 to 3.9%.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9801341      PMCID: PMC96208          DOI: 10.1128/CDLI.5.6.817-822.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  22 in total

1.  A simple test for predisposition to LDL oxidation based on the fluorescence development during copper-catalyzed oxidative modification.

Authors:  L Cominacini; U Garbin; A Davoli; R Micciolo; O Bosello; G Gaviraghi; L A Scuro; A M Pastorino
Journal:  J Lipid Res       Date:  1991-02       Impact factor: 5.922

Review 2.  Lipoproteins in normal and atherosclerotic aorta.

Authors:  S Ylä-Herttuala; W Palinski; M E Rosenfeld; D Steinberg; J L Witztum
Journal:  Eur Heart J       Date:  1990-08       Impact factor: 29.983

3.  Comparison of analytical methods for monitoring autoxidation profiles of authentic lipids.

Authors:  R S Kim; F S LaBella
Journal:  J Lipid Res       Date:  1987-09       Impact factor: 5.922

4.  Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL.

Authors:  S Ylä-Herttuala; W Palinski; S W Butler; S Picard; D Steinberg; J L Witztum
Journal:  Arterioscler Thromb       Date:  1994-01

5.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis.

Authors:  J T Salonen; S Ylä-Herttuala; R Yamamoto; S Butler; H Korpela; R Salonen; K Nyyssönen; W Palinski; J L Witztum
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

6.  Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation.

Authors:  H F Hoff; J O'Neil
Journal:  Arterioscler Thromb       Date:  1991 Sep-Oct

7.  Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits.

Authors:  M E Haberland; D Fong; L Cheng
Journal:  Science       Date:  1988-07-08       Impact factor: 47.728

8.  Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit.

Authors:  H C Boyd; A M Gown; G Wolfbauer; A Chait
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

9.  Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers.

Authors:  G Virella; I Virella; R B Leman; M B Pryor; M F Lopes-Virella
Journal:  Int J Clin Lab Res       Date:  1993

10.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.

Authors:  S Ylä-Herttuala; W Palinski; M E Rosenfeld; S Parthasarathy; T E Carew; S Butler; J L Witztum; D Steinberg
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

View more
  2 in total

Review 1.  Lipoprotein autoantibodies: measurement and significance.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells.

Authors:  Samar M Hammad; Waleed O Twal; Jeremy L Barth; Kent J Smith; Antonio F Saad; Gabriel Virella; W Scott Argraves; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-05-28       Impact factor: 5.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.